Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.800
-0.060 (-3.23%)
Nov 4, 2024, 4:00 PM EST - Market closed

BCLI Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
9.3810.6910.879.39.365.8
Upgrade
Research & Development
6.9110.7513.9615.2422.3317.2
Upgrade
Operating Expenses
16.321.4424.8224.5431.6823
Upgrade
Operating Income
-16.3-21.44-24.82-24.54-31.68-23
Upgrade
Interest Expense
-0.45-0.28---0.13-0.25
Upgrade
Interest & Investment Income
--0.550.08--
Upgrade
Other Non Operating Income (Expenses)
44.53----
Upgrade
Pretax Income
-12.75-17.19-24.28-24.46-31.81-23.25
Upgrade
Net Income
-12.75-17.19-24.28-24.46-31.81-23.25
Upgrade
Net Income to Common
-12.75-17.19-24.28-24.46-31.81-23.25
Upgrade
Shares Outstanding (Basic)
432221
Upgrade
Shares Outstanding (Diluted)
432221
Upgrade
Shares Change (YoY)
54.99%17.99%0.90%21.22%36.25%9.54%
Upgrade
EPS (Basic)
-3.30-5.99-9.97-10.14-15.99-15.92
Upgrade
EPS (Diluted)
-3.31-6.00-9.97-10.20-15.99-15.92
Upgrade
Free Cash Flow
-14.46-20.48-19.35-26.6-35.57-11.72
Upgrade
Free Cash Flow Per Share
-3.74-7.13-7.95-11.03-17.88-8.03
Upgrade
EBITDA
-16.04-21.17-24.54-24.28-31.47-22.84
Upgrade
D&A For EBITDA
0.260.270.290.260.220.16
Upgrade
EBIT
-16.3-21.44-24.82-24.54-31.68-23
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.